Bayesian Design of Proof-of-Concept Trials

被引:41
作者
Fisch, Roland [1 ]
Jones, Ieuan [1 ]
Jones, Julie [1 ]
Kerman, Jouni [1 ]
Rosenkranz, Gerd Karl [1 ]
Schmidli, Heinz [1 ]
机构
[1] Novartis Pharma AG, Dev Biometr & Stat Sci, CH-4002 Basel, Switzerland
关键词
Bayesian inference; clinical trials; decision criteria; operating characteristics; phase IIa; proof of concept; CLINICAL-TRIALS; DRUG DEVELOPMENT; INFORMATION;
D O I
10.1177/2168479014533970
中图分类号
R-058 [];
学科分类号
摘要
The proof-of-concept (PoC) decision is a key milestone in the clinical development of an experimental treatment. A decision is taken on whether the experimental treatment is further developed (GO), whether its development is stopped (NO-GO), or whether further information is needed to make a decision. The PoC decision is typically based on a PoC clinical trial in patients comparing the experimental treatment with a control treatment. It is important that the PoC trial be designed such that a GO/NO-GO decision can be made. The present work develops a generic, Bayesian framework for defining quantitative PoC criteria, against which the PoC trial results can be assessed. It is argued that PoC criteria based solely on significance testing versus the control are not appropriate in this decision context. A dual PoC criterion is proposed that includes assessment of superiority over the control and relevance of the effect size and hence better matches clinical decision making. The approach is illustrated for 2 PoC trials in cystic fibrosis and psoriasis.
引用
收藏
页码:155 / 162
页数:8
相关论文
共 22 条
[1]   Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial [J].
Baeten, Dominique ;
Baraliakos, Xenofon ;
Braun, Juergen ;
Sieper, Joachim ;
Emery, Paul ;
van der Heijde, Desiree ;
McInnes, Iain ;
van Laar, Jacob M. ;
Landewe, Robert ;
Wordsworth, Paul ;
Wollenhaupt, Juergen ;
Kellner, Herbert ;
Paramarta, Jacqueline ;
Wei, Jiawei ;
Brachat, Arndt ;
Bek, Stephan ;
Laurent, Didier ;
Li, Yali ;
Wang, Ying A. ;
Bertolino, Arthur P. ;
Gsteiger, Sandro ;
Wright, Andrew M. ;
Hueber, Wolfgang .
LANCET, 2013, 382 (9906) :1705-1713
[2]   Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis [J].
Bansback, Nick ;
Sizto, Sonia ;
Sun, Huiying ;
Feldman, Steven ;
Willian, Mary Kaye ;
Anis, Aslam .
DERMATOLOGY, 2009, 219 (03) :209-218
[3]  
Bedding A., 2004, PHARM STAT, P406, DOI [DOI 10.1002/PST.130, 10.1002/pst.130,3(3),230-231.http://www.wileyeurope.com/WileyCDA/WileyTitle]
[4]  
Berry SM, 2010, CH CRC BIOSTAT SER, P1, DOI 10.1201/EBK1439825488
[5]   Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice [J].
Cartwright, M. E. ;
Cohen, S. ;
Fleishaker, J. C. ;
Madani, S. ;
McLeod, J. F. ;
Musser, B. ;
Williams, S. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) :278-285
[6]   The role of the minimum clinically important difference and its impact on designing a trial [J].
Chuang-Stein, Christy ;
Kirby, Simon ;
Hirsch, Ian ;
Atkinson, Gary .
PHARMACEUTICAL STATISTICS, 2011, 10 (03) :250-256
[7]   A Quantitative Approach for Making Go/No-Go Decisions in Drug Development [J].
Chuang-Stein, Christy ;
Kirby, Simon ;
French, Jonathan ;
Kowalski, Ken ;
Marshall, Scott ;
Smith, Mike K. ;
Bycott, Paul ;
Beltangady, Mohan .
DRUG INFORMATION JOURNAL, 2011, 45 (02) :187-202
[8]   Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs [J].
DiMasi, J. A. ;
Feldman, L. ;
Seckler, A. ;
Wilson, A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) :272-277
[9]   Bayesian predictive approach to interim monitoring in clinical trials [J].
Dmitrienko, A ;
Wang, MD .
STATISTICS IN MEDICINE, 2006, 25 (13) :2178-2195
[10]   SAMPLING-BASED APPROACHES TO CALCULATING MARGINAL DENSITIES [J].
GELFAND, AE ;
SMITH, AFM .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1990, 85 (410) :398-409